| 2.98 Data as of Jun 18 |  -0.02 / -0.67%Today’s Change | 1.62 Today|||52-Week Range 5.14 | +48.26% Year-to-Date |
| Previous close | 3.00 |
| Today’s open | 2.98 |
| Day’s range | -- - -- |
| Volume | 173,159 |
| Average volume (3 months) | 232,339 |
| Market cap | $179.1M |
| Dividend yield | -- |
| Earnings growth (last year) | -669.98% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +34.27% |
| P/E ratio | -- |
| Price/Sales | 5.43 |
| Price/Book | 3.06 |
| Today’s change | Today’s % change | |
|---|---|---|
| TEVATeva Pharmaceutical ... | +0.32 | +0.81% |
| Next reporting date | August 20, 2013 |
| EPS forecast (this quarter) | -$0.05 |
| Annual revenue (last year) | $25.9M |
| Annual profit (last year) | -$16.8M |
| Net profit margin | -64.84% |
Sector Health Technology |
Industry Pharmaceuticals: Generic |
President, Chief Executive Officer & Director Henri Harland, MBA |
CFO, VP-Administration & Head-Investor Relations André Godin |
Corporate headquarters Laval, Québec |
.
